甲状腺球蛋白的测量是分化型甲状腺癌现代管理的基石，临床治疗和随访的决策都基于这些测量结果。然而，关于甲状腺球蛋白测量及结果解读存在许多需要考虑的因素。本文提供了对我们团队关于这些问题的2013年和2014年分别发布的临床立场文件的整合更新。这篇文献将根据对现有文献的广泛分析，对高敏感甲状腺球蛋白测量的分析和临床方面的问题进行回顾和讨论。甲状腺球蛋白的测量仍然是一个非常复杂的过程，存在许多陷阱和重大干扰因素，特别是抗甲状腺球蛋白抗体，需要进行评估、考虑，并在必要时进行适当处理。我们的专家共识团队提出了53个实用、分级的建议，用于指导实验室和临床实践中的高敏感甲状腺球蛋白和TgAb，并且在当前指南未提供足够指导的情况下特别有价值。© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology.

Thyroglobulin measurement is the cornerstone of modern management of differentiated thyroid cancer, with clinical decisions on treatment and follow-up based on the results of such measurements. However, numerous factors need to be considered regarding measurement with and interpretation of thyroglobulin assay results.The present document provides an integrated update to the 2013 and 2014 separate clinical position papers of our group on these issues.Issues concerning analytical and clinical aspects of highly-sensitive thyroglobulin measurement will be reviewed and discussed based on an extensive analysis of the available literature.Thyroglobulin measurement remains a highly complex process with many pitfalls and major sources of interference, especially anti-thyroglobulin antibodies, need to be assessed, considered and, when necessary, dealt with appropriately.Our expert consensus group formulated 53 practical, graded recommendations for guidance on highly-sensitive thyroglobulin and TgAb in laboratory and clinical practice, especially valuable where current guidelines do not offer sufficient guidance.© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology.